Neoadjuvant and Adjuvant Pembrolizumab for the Treatment of Early-Stage Resectable Non-small Cell Lung Cancer An Editorial Regarding the Interim Data Analysis of the KEYNOTE-671 Phase III Trial of Neoadjuvant and Adjuvant Pembrolizumab

Ann Surg Oncol. 2024 Jan;31(1):4-5. doi: 10.1245/s10434-023-14356-9. Epub 2023 Oct 26.
No abstract available

Publication types

  • Editorial

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols
  • Carcinoma, Non-Small-Cell Lung* / drug therapy
  • Carcinoma, Non-Small-Cell Lung* / surgery
  • Clinical Trials, Phase III as Topic
  • Humans
  • Lung Neoplasms* / drug therapy
  • Lung Neoplasms* / surgery
  • Neoadjuvant Therapy
  • Small Cell Lung Carcinoma*

Substances

  • pembrolizumab